Key Insights

Highlights

Success Rate

85% trial completion

Published Results

36 trials with published results (6%)

Research Maturity

209 completed trials (36% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

6.6%

38 terminated out of 579 trials

Success Rate

84.6%

-1.9% vs benchmark

Late-Stage Pipeline

14%

79 trials in Phase 3/4

Results Transparency

17%

36 of 209 completed with results

Key Signals

36 with results85% success38 terminated

Data Visualizations

Phase Distribution

361Total

Not Applicable (180)

Early P 1 (5)

P 1 (43)

P 2 (54)

P 3 (41)

P 4 (38)

Trial Status

Completed209

Unknown200

Recruiting58

Not Yet Recruiting39

Terminated38

Active Not Recruiting16

Trial Success Rate

84.6%

Benchmark: 86.5%

Based on 209 completed trials

Clinical Trials (579)

Showing 20 of 20 trials

NCT07571460Phase 4CompletedPrimary

Clinical Application of Simcyp-Guided Warfarin Initiation Doses in Cirrhotic Patients With Portal Vein Thrombosis

NCT07571876Not Yet Recruiting

Ultrasound Prediction of Esophageal Variceal Bleeding Risk

NCT07151885Not ApplicableRecruitingPrimary

The Diagnostic Value of Subharmonic Imaging Technology Combined With Liver Stiffness and Platelet Count for High-risk Esophageal and Gastric Varices in Patients With Liver Cirrhosis

NCT07561138Not ApplicableRecruiting

Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation

NCT06144086Phase 2CompletedPrimary

A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)

NCT06576934Not ApplicableRecruitingPrimary

Early TIPS in Patients With Liver Cirrhosis and Ascites

NCT07490405Not Yet RecruitingPrimary

Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism

NCT07560202Active Not RecruitingPrimary

Portal Vein Thrombosis in Liver Cirrhosis: Clinical Characteristics, Radiological Patterns, and Predictors

NCT05782556RecruitingPrimary

Freiburg TIPS Registry

NCT07325526Phase 2RecruitingPrimary

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

NCT07553858Not ApplicableNot Yet Recruiting

Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy

NCT07298577Not ApplicableEnrolling By InvitationPrimary

Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer

NCT06050993CompletedPrimary

Effects of Platelet Mimicking Nanoparticles in Patients With Cirrhosis

NCT02551250CompletedPrimary

Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis

NCT07439939RecruitingPrimary

Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement

NCT07347275Phase 3Not Yet Recruiting

A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.

NCT07529262Phase 3Not Yet RecruitingPrimary

Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial

NCT06256432Phase 2Active Not Recruiting

Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome